Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:DCPH

Deciphera Pharmaceuticals (DCPH) Stock Price, News & Analysis

Deciphera Pharmaceuticals logo

About Deciphera Pharmaceuticals Stock (NASDAQ:DCPH)

Key Stats

Today's Range
$25.59
$25.59
50-Day Range
$25.55
$25.59
52-Week Range
$9.90
$25.61
Volume
600 shs
Average Volume
1.29 million shs
Market Capitalization
$2.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Deciphera Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
11th Percentile Overall Score

DCPH MarketRank™: 

Deciphera Pharmaceuticals scored higher than 11% of companies evaluated by MarketBeat, and ranked 930th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Deciphera Pharmaceuticals.

  • Earnings Growth

    Earnings for Deciphera Pharmaceuticals are expected to grow in the coming year, from ($2.15) to ($1.77) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Deciphera Pharmaceuticals is -11.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Deciphera Pharmaceuticals is -11.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Deciphera Pharmaceuticals has a P/B Ratio of 5.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for DCPH.
  • Dividend Yield

    Deciphera Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Deciphera Pharmaceuticals does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for DCPH.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Deciphera Pharmaceuticals this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Deciphera Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.67% of the stock of Deciphera Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    70.96% of the stock of Deciphera Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Deciphera Pharmaceuticals' insider trading history.
Receive DCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DCPH Stock News Headlines

Nvidia CEO Makes First Ever Tesla Announcement
While headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $25 trillion AI revolution — one that Nvidia’s CEO himself has called a “multi-trillion-dollar future industry” — and he’s uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough.tc pixel
See More Headlines

DCPH Stock Analysis - Frequently Asked Questions

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) announced its quarterly earnings data on Tuesday, February, 6th. The company reported ($0.54) EPS for the quarter, beating analysts' consensus estimates of ($0.58) by $0.04. The company's quarterly revenue was up 32.9% compared to the same quarter last year.
Read the conference call transcript
.

Deciphera Pharmaceuticals (DCPH) raised $101 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

Last Earnings
2/06/2024
Today
9/18/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:DCPH
CIK
1654151
Fax
N/A
Employees
300
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($2.21)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$194.94 million
Net Margins
-108.86%
Pretax Margin
-108.62%
Return on Equity
-52.42%
Return on Assets
-40.05%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.19
Quick Ratio
3.94

Sales & Book Value

Annual Sales
$174.91 million
Price / Sales
12.65
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.38 per share
Price / Book
5.84

Miscellaneous

Outstanding Shares
86,476,000
Free Float
82,438,000
Market Cap
$2.21 billion
Optionable
Optionable
Beta
0.19

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:DCPH) was last updated on 9/18/2025 by MarketBeat.com Staff
From Our Partners